* Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 and 3 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
† Data from this study was collected with the outside US version of the FreeStyle Libre 2 system. FreeStyle Libre 3 has the same features as FreeStyle Libre 2 system. Therefore the study data is applicable to both products.
‡ Based on assessment and input from patient’s healthcare provider.
§ Notifications will only be received when alarms are turned on and the sensor is within 20 feet of the reading device.
References: 1. Bolinder, Jan, et al. "Novel Glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-masked, Randomised Controlled Trial." The Lancet 388, no. 10057 (2016): 2254-2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 2. Evans, Mark, et al. "Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 months: a meta-analysis of 75 real-world observational studies." Diabetes Therapy (April 2022). https://doi.org/10.1007/s13300-022-01253-9. 3. Haak, Thomas, et al. "Flash Glucose-sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (2017): 55–73. https://doi.org/10.1007/s13300-016-0223-6. 4. Riveline Jean-Pierre et. al. “Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study.” Diabetes Technology & Therapeutics 24, no. 9 (2022): 611–618. https://doi.org/10.1089/dia.2022.0085. 5. Aronson, Ronnie, et al. “IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. Diabetes Obesity and Metabolism 25, no. 4 (2023): 1024–1031. https://doi.org/10.1111/dom.14949. 6. Leelarathna, Lalantha, et al. "Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes." New England Journal of Medicine 387, no. 16 (2022): 1477–1487. https://doi.org/10.1056/nejmoa2205650. 7. Data on file. Abbott Diabetes Care, Inc.
ADC-95730 v1.0
